• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导放化疗后非小细胞肺癌持续病理性 N2 IIIA 期患者的手术治疗:显微镜下的怀疑种子。

Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.

机构信息

Department of General Thoracic Surgery, Catholic University, Rome, Italy.

出版信息

Eur J Cardiothorac Surg. 2011 Sep;40(3):656-63. doi: 10.1016/j.ejcts.2010.12.062. Epub 2011 Mar 12.

DOI:10.1016/j.ejcts.2010.12.062
PMID:21402479
Abstract

OBJECTIVE

The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT) for locally advanced cIIIA-N2 non-small-cell lung cancer (NSCLC) is still debated. The long-term results after resection in a pN2 series are at the focus of this study.

METHODS

From January 1992 to December 2008, 161 consecutive pathologically proven Stage IIIA-N2 NSCLC patients underwent IT. Among these, 40 pN2s were included in this retrospective analysis. The associations between the mortality and the disease-free status with potential risk factors were explored by means of the Kaplan-Meier and Cox regression analysis.

RESULTS

Mean age and male/female ratio were 58.7 ± 9.7 years and 36/4, respectively. Twelve patients (30%) showed a clinical partial response and 28 (70%) showed stable disease. There was one (3%) perioperative death and four (10%) major complications. In the total group, the 3- and 5-year survival rates were 24.2% and 19.3%, respectively. The Cox regression analysis suggested that the macroscopic pN2 status proved to be a negative prognostic factor (hazard ratio (HR)=2.8, confidence interval (CI) 95%: 1.1-7.3; p=0.04). The recurrence rate flattened at 30.8% at the 3rd year. Furthermore, the bilobectomy-pneumonectomy group had a risk of relapse 6.9 times higher than the lobectomy group (CI 95%: 2.5-18.8; p < 0.001).

CONCLUSIONS

The persistence of disease at the N2 level after IT and surgery for cIIIa-N2 NSCLC does not exclude favorable outcome after resection, in particular in those patients with minor residual disease.

摘要

目的

诱导放化疗(IT)后局部晚期 cIIIA-N2 非小细胞肺癌(NSCLC)残留 N2 疾病的手术治疗仍存在争议。本研究重点关注 N2 系列切除后的长期结果。

方法

1992 年 1 月至 2008 年 12 月,连续 161 例经病理证实的 IIIA-N2 期 NSCLC 患者接受 IT。其中,40 例 pN2 患者纳入本回顾性分析。采用 Kaplan-Meier 和 Cox 回归分析探讨潜在危险因素与死亡率和无病状态的关系。

结果

患者平均年龄和男女比例分别为 58.7±9.7 岁和 36/4。12 例(30%)患者表现为临床部分缓解,28 例(70%)患者病情稳定。围手术期死亡 1 例(3%),严重并发症 4 例(10%)。在总组中,3 年和 5 年生存率分别为 24.2%和 19.3%。Cox 回归分析表明,宏观 pN2 状态是一个负预后因素(风险比(HR)=2.8,95%置信区间(CI):1.1-7.3;p=0.04)。第 3 年时,复发率稳定在 30.8%。此外,肺叶切除加全肺切除术组的复发风险是肺叶切除术组的 6.9 倍(95%CI:2.5-18.8;p<0.001)。

结论

IT 及手术治疗后 cIIIa-N2 NSCLC 患者 N2 水平仍存在疾病残留并不排除切除后的良好预后,特别是残留疾病较少的患者。

相似文献

1
Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.诱导放化疗后非小细胞肺癌持续病理性 N2 IIIA 期患者的手术治疗:显微镜下的怀疑种子。
Eur J Cardiothorac Surg. 2011 Sep;40(3):656-63. doi: 10.1016/j.ejcts.2010.12.062. Epub 2011 Mar 12.
2
Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.基线可切除 IIIA-N2 期非小细胞肺癌的外科多模态治疗。纵隔淋巴结受累程度及对生存的影响。
Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.
3
Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.局部晚期(IIIA-IIIB期)肺癌新辅助治疗后肺切除术的结果。
Eur J Cardiothorac Surg. 2006 Jul;30(1):184-9. doi: 10.1016/j.ejcts.2006.03.054. Epub 2006 May 26.
4
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.IIIA-N2期非小细胞肺癌诱导化疗后手术切除与放射治疗的随机对照试验
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50. doi: 10.1093/jnci/djk093.
5
Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?肺切除术:在 III 期非小细胞肺癌的三联疗法中可计算或不可耐受的风险因素?
Eur J Cardiothorac Surg. 2012 Apr;41(4):880-5; discussion 885. doi: 10.1093/ejcts/ezr160. Epub 2012 Jan 10.
6
Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.诱导治疗后持续存在的N2期疾病不会危及肺切除术的早期和中期结果。
Ann Thorac Surg. 2008 Jul;86(1):228-33. doi: 10.1016/j.athoracsur.2008.01.019.
7
Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures.所有适应证均重复纵隔镜检查:96 例患者 101 次操作的经验。
Eur J Cardiothorac Surg. 2011 Jun;39(6):1022-7. doi: 10.1016/j.ejcts.2010.10.019. Epub 2010 Nov 26.
8
Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer.诱导放化疗后手术治疗局部晚期非小细胞肺癌患者病理完全缓解的长期结果。
Eur J Cardiothorac Surg. 2013 Mar;43(3):e71-81. doi: 10.1093/ejcts/ezs622. Epub 2013 Jan 4.
9
Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.病理分期为IIIA期N2非小细胞肺癌患者中pN2亚分类的验证
Interact Cardiovasc Thorac Surg. 2011 May;12(5):733-8. doi: 10.1510/icvts.2010.249896. Epub 2011 Feb 5.
10
Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer.非小细胞肺癌袖状肺叶切除术后的发病率、死亡率和长期生存率
Eur J Cardiothorac Surg. 2007 Jan;31(1):95-102. doi: 10.1016/j.ejcts.2006.10.031. Epub 2006 Nov 28.

引用本文的文献

1
A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.术后立体定向体部放射治疗(SBRT)治疗 III 期非小细胞肺癌的初步研究。
BMC Cancer. 2018 Nov 29;18(1):1183. doi: 10.1186/s12885-018-5039-5.
2
Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.IIIA/N2期非小细胞肺癌三联疗法中与治疗相关的预测和预后因素
Front Oncol. 2018 Feb 20;8:30. doi: 10.3389/fonc.2018.00030. eCollection 2018.
3
Transition from thoracotomy to uniportal video-assisted thoracic surgery in non-small cell lung cancer-the Oslo experience.
非小细胞肺癌手术从开胸手术向单孔电视辅助胸腔镜手术的转变——奥斯陆经验
J Vis Surg. 2016 Jun 29;2:111. doi: 10.21037/jovs.2016.06.09. eCollection 2016.
4
Clinical value of nodal micrometastases in patients with non-small cell lung cancer: time for reconsideration?非小细胞肺癌患者淋巴结微转移的临床价值:是否需要重新审视?
J Thorac Dis. 2016 Dec;8(12):E1755-E1758. doi: 10.21037/jtd.2016.12.83.
5
CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.CMTM1_v17与非小细胞肺癌的化疗耐药性及不良预后相关。
World J Surg Oncol. 2017 Jan 28;15(1):34. doi: 10.1186/s12957-016-1094-z.
6
Translocation of left inferior lobe pulmonary artery to the pulmonary artery trunk for central type non-small cell lung cancers.左肺下叶肺动脉转位至肺动脉干治疗中央型非小细胞肺癌
J Thorac Dis. 2016 May;8(5):826-32. doi: 10.21037/jtd.2016.03.35.
7
Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins.侵犯左心房或肺静脉心包内基部的T(4)期非小细胞肺癌的手术结果及长期随访
Interact Cardiovasc Thorac Surg. 2012 Apr;14(4):415-9. doi: 10.1093/icvts/ivr160. Epub 2012 Jan 22.